Business Description
DBV Technologies SA
ISIN : FR0010417345
Share Class Description:
CHIX:DBVp: Ordinary SharesTotal Employee Number:
161Compare
Compare
Traded in other countries / regions
DBV.FranceDBVT.USADBV.Germany0QAJ.UK IPO Date
2013-07-15Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 37.58 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 5.8 | |||||
3-Year EPS without NRI Growth Rate | 8.5 | |||||
3-Year FCF Growth Rate | -2.7 | |||||
3-Year Book Growth Rate | -32.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 423.15 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 1.39 | |||||
9-Day RSI | 5.83 | |||||
14-Day RSI | 9.26 | |||||
3-1 Month Momentum % | -12.64 | |||||
6-1 Month Momentum % | -12.88 | |||||
12-1 Month Momentum % | -10.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.76 | |||||
Quick Ratio | 4.76 | |||||
Cash Ratio | 4.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -35.8 | |||||
Shareholder Yield % | -37.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -161.28 | |||||
ROA % | -103.57 | |||||
ROIC % | -528.4 | |||||
3-Year ROIIC % | 773.09 | |||||
ROC (Joel Greenblatt) % | -1056.75 | |||||
ROCE % | -151.23 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 27.8 | |||||
PB Ratio | 4.71 | |||||
Price-to-Tangible-Book | 4.7 | |||||
EV-to-EBIT | -4.5 | |||||
EV-to-EBITDA | -4.73 | |||||
EV-to-Forward-Revenue | 192.73 | |||||
EV-to-FCF | -5.02 | |||||
| Price-to-Net-Current-Asset-Value | 5.2 | |||||
| Price-to-Net-Cash | 5.71 | |||||
Earnings Yield (Greenblatt) % | -22.22 | |||||
FCF Yield % | -15.32 |
GF Valueâ„¢
DBV Technologies SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DBV Technologies SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-28 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 | In 29 days | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 09:20 | 3.23 (+0.00%) | ||
| General meeting for 2026 | 2026-06-03 10:00 | 3.23 (+0.00%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 09:00 | 3.70 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 3.70 (+0.00%) | ||
| Annual report for 2025 | 2026-03-26 | 3.70 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 3.70 (+0.00%) | ||
| Citizens Life Sciences Conference | 2026-03-10 13:40 | 3.70 (+0.00%) | ||
| Guggenheim Securities Emerging Outlook: Biotech Summit | 2026-02-12 14:30 | 3.97 (+0.00%) |
Show
Entries
Press Release
Articles on DBV Technologies SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers